Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for Prevention of RA in Undifferentiated Arthritis
NCT00124449Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2005
- Primary completion
- May 2007
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Abatacept with Placebo (2 arms). Primary endpoint: Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) at 12 months. Started Feb 2005; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00124449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124449.